Thomas Dipetrillo is an Oncology physician affiliated with Brown University. OpenAlex indexes 242 publications with 7,042 citations (h-index 48); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
593 Eddy St
Providence, RI 029034923
Telephone
401-444-8311Provider last certified this registry record 18 May 2026.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20252 payments
- Elekta, Inc.Program year20222 payments
- Zimmer Biomet Holdings, Inc.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
37.1%alpha-Adrenergic Blocker37.1%Tamsulosin Hcl100%Part D<11 patientsNervous system
31.4%Opioid Agonist31.4%Oxycodone-Acetaminophen100%Part D<11 patientsMetabolism & gastrointestinal
31.4%Corticosteroid31.4%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head
American Journal of Clinical Oncology
2020 - Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study
International Journal of Radiation Oncology*Biology*Physics
2016 - Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized trial
Journal of Thoracic and Cardiovascular Surgery
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Frank Sellke, MD
Brown University
Josiah Rich, MD
Brown University
Donald Coustan, MD
Brown University
Audrey Tyrka, MD, PhD
Brown University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”